Idarubicin (hydrochloride), CAS 57852-57-0

Product Description: Idarubicin hydrochloride is an anthracycline antileukemic agent. It inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin hydrochloride inhibits the growth of bacteria and yeasts.

Applications: Cancer-programmed cell death

Formula: C26H28ClNO9

Citations: Anal Chem. 2022 Oct 4;94(39):13623-13630./bioRxiv. 2023 Jan 13./Cancer Lett. 2019 Oct 1;461:31-43. /Exp Cell Res. 2020 Aug 1;393(1):112054./J Mol Med (Berl). 2019 Aug;97(8):1183-1193./J Virol. 2019 May 15;93(11):e02230-18. /Nat Commun. 2020 Apr 14;11(1):1792./Nucleic Acids Res. 2018 Apr 20;46(7):3284-3297./University of Paris. 2022 Sep 19./Viruses. 2020 Jun 10;12(6):628./Mol Carcinog. 2023 Jul 26.

References: [1]Orlandi P, et al. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids. J Chemother. 2005 Dec;17(6):663-7./[2]Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993 Apr;24(4):275-88./[3]Siegsmund MJ, et al. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells. Eur Urol. 1997;31(3):365-70./[4]Gewirtz DA, et al. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol. 1998;41(5):361-/[5]Kinnunen U, et al. Idarubicin inhibits the growth of bacteria and yeasts in an automated blood culture system. Eur J Clin Microbiol Infect Dis. 2009 Mar;28(3):301-3.

CAS Number: 57852-57-0

Molecular Weight: 533.95

Compound Purity: 99.94

Research Area: Cancer; Infection

Solubility: DMSO : 83.33 mg/mL (ultrasonic)

Target: Antibiotic;Autophagy;Bacterial;c-Myc;DNA/RNA Synthesis;Fungal;Topoisomerase

• Artikelnummer: MEXHY-17381-100
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-17381-100
• Green Labware: Nein
• Verpackungseinheit: 100 mg
• Mengeneinheit: STK